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When the short-term primary endpoint of a randomized
study is met, generally, the long-term secondary endpoint
analysis is less relevant, and not infrequently, the acute
beneﬁt of a treatment is diluted or not maintained over
time. This is not the case for the METOCARD-CNIC
(Metoprolol in Cardioprotection During an Acute Myo-
cardial Infarction) trial (1,2). In this issue of the Journal,
Ibanez et al. (2) report the long-term results of a primary
percutaneous coronary intervention (PCI) randomized trial
that assessed the impact on infarct size of intravenousSee page 2356metoprolol administration before mechanical intervention
in patients with acute anterior myocardial infarction. The
primary endpoint of the study was infarct size as assessed
by magnetic resonance imaging (MRI) at 1 week after
intervention. The primary endpoint of the study was met:
patients randomized to metoprolol had smaller infarcts than
control subjects (25.6  15.3 g vs. 32.0  22.2 g; adjusted
difference 6.52; 95% conﬁdence interval [CI]: 11.39
to 1.78; p ¼ 0.012), and this effect was evident just in
patients with an occluded infarct artery before intervention
(26.7  15.0 g in metoprolol patients vs. 34.4  20.0 g
in the control group, adjusted difference 8.13; 95%
CI: 13.10 to 3.16; p ¼ 0.0024), whereas no signiﬁcant
effect was revealed in patients with an already open infarct
artery at baseline angiography (20.7  16.4 g in the meto-
prolol group vs. 22.2  28.3 g in the control group, p¼ 0.6),
conﬁrming that pre-intervention metoprolol is effective in
decreasing reperfusion myocardial damage (1). At 6 months,
202 patients (101 per group) of the 216 eligible patients
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disclose.severe left ventricular remodeling and dysfunction in the
metoprolol group: a left ventricular ejection fraction <35%
was revealed in 11% of patients in the metoprolol group
and 27% in the control group, p ¼ 0.006 (2). Again, at
2-year follow-up, the rate of readmission for congestive
heart failure was more than halved in the metoprolol
group (2.2% vs. 6.9%; p ¼ 0.046), as well as the number of
patients who received cardioverter-deﬁbrillator implan-
tation (2). The survival curves of readmission for con-
gestive heart failure continue to diverge after 1 year,
conﬁrming that the early beneﬁt of pre-intervention
metoprolol may increase over time according to the long
process of left ventricular remodeling toward clinical
heart failure.
Thus, despite the fact that the study was not powered for
clinical endpoints, the results of the MRI and clinical
follow-up suggest a strong impact of pre-reperfusion
metoprolol on clinical outcome with obvious economic
implications.
Several characteristics of the METOCARD-CNIC trial
deserve speciﬁc comments in order to understand the
strengths of the study. First, the inclusion criteria included
only anterior myocardial infarctions without hemodynamic
instability, allowing the recruitment of large myocardial in-
farctions without safety issues as a result of the negative
inotropic effect of metoprolol. Second, this is mechanistic
trial that included in the protocol a paired MRI to assess the
effects of infarct size on left ventricular remodeling over
time, and the MRI follow-up rate was very high, making the
demonstration of the link between infarct size and left
ventricular remodeling unquestionable. Third, the effects of
pre-intervention metoprolol on infarct size, left ventricular
remodeling, and readmission for congestive heart failure
were evident despite the fact that approximately 20% of
patients who received the drug had an already open infarct
artery at the time of intervention, rendering the drug inef-
fective in terms of prevention of reperfusion damage. Finally,
the rates of all components of the composite clinical end-
point of death from any cause, malignant ventricular ar-
rhythmias, reinfarction, and admission for congestive heart
failure were better in the metoprolol arm, with a resulting
strong trend favoring metoprolol (endpoint rate 10.8%
in the metoprolol arm and 18.3% in the control arm,
p ¼ 0.065). The clinical implications of this result are
important despite the p value, when considering the small
number of patients, the inclusion in the endpoint of patients
who died from noncardiac causes that were not related to the
study treatment, and the high likelihood of a progressive
increase in adverse events in the control arm during a longer
follow-up.
It is surprising that the METOCARD-CNIC trial is the
ﬁrst randomized study on adjunctive beta-blocker treatment
before mechanical intervention, considering that a strong
beneﬁt of pre-reperfusion beta-blocker treatment was al-
ready suggested many years ago in retrospective analyses
from the PAMI (Primary Angioplasty in Acute Myocardial
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and Device Investigation to Lower Late Angioplasty
Complications) trials (3,4). In these post-hoc analyses, pa-
tients who received a beta-blocker before PCI had a strong
beneﬁt in short-term survival as compared with patients who
did not receive the drug. In the CADILLAC patient cohort,
the beneﬁt was entirely limited to patients who did not
receive the drug before admission, and the multivariable
analysis showed pre-intervention beta-blocker treatment
independently related with 30-day mortality (hazard ratio:
0.38, 95% CI: 0.17 to 0.87, p ¼ 0.02) (4). From those years,
a plethora of studies with drugs or devices were conducted to
reduce reperfusion myocardial damage. Most of these
studies, including large empirical pharmacology trials or
smaller mechanistic device trials, failed to demonstrate any
beneﬁt. Also, studies using complex and expensive tech-
niques, such as cooling and hyperoxemic reperfusion, have
not provided convincing results. Thus, until now, restoring a
full (microvascular) reperfusion while avoiding reperfusion
damage has remained elusive in many patients despite the
evidence of cardioprotection exerted by many agents and
techniques in animal models.
The results of the trial are particularly appealing because
they show that an effective cardioprotection can be achieved
with intravenous metoprolol before reperfusion at a very low
price and with ease of administration. These characteristics
make highly feasible a clinical trial powered for long-term
clinical endpoints such as cardiac mortality and congestiveheart failure that will provide a deﬁnite answer to the routine
use of beta-blockers before mechanical myocardial reperfu-
sion in acute myocardial infarction.
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